title: Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
abstract: BACKGROUND
  Chronic infection with Burkholderia cepacia complex (BCC) has a detrimental effect on morbidity and mortality for patients with cystic fibrosis (CF). It is therefore logical to attempt to eradicate new isolates however there is a paucity of information to guide treatment. We report the successful eradication of new isolates of BCC in two children with CF.
  
  
  METHODS
  Burkholderia cepacia was successfully eradicated in a 14 year old boy with CF and Burkholderia gladioli was successfully eradicated in a six year old girl with CF. In both children two weeks of intravenous (IV) tobramycin, ceftazidime and temocillin were used followed by three months of inhaled tobramycin. Bronchoalveolar lavage samples taken during flexible bronchoscopy were used prior to treatment to exclude spontaneous clearance as well as after treatment to confirm eradication.
  
  
  CONCLUSIONS
  New isolates of BCC can be successfully eradicated in children with CF. More research is urgently required in this area to identify the best treatment regimen for BCC eradication.
authors.affiliation: Royal Stoke University Hospital, Stoke on Trent, ST4 6QG, UK.
authors.forename: H
authors.initials: H
authors.lastname: Kitt
authors.affiliation: Royal Stoke University Hospital, Stoke on Trent, ST4 6QG, UK.
authors.forename: W
authors.initials: W
authors.lastname: Lenney
authors.affiliation: Royal Stoke University Hospital, Stoke on Trent, ST4 6QG, UK. francis.gilchrist@uhns.nhs.uk.|Academic Department of Child Health, Royal Stoke University Hospital, Newcastle Road, Stoke on Trent, ST4 6QG, UK. francis.gilchrist@uhns.nhs.uk.
authors.forename: F J
authors.initials: FJ
authors.lastname: Gilchrist
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D019121:Burkholderia Infections / Q000150:complications / Q000188:drug therapy*; D042602:Burkholderia cepacia complex / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D002442:Ceftazidime / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D004739:England; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014031:Tobramycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010406:Penicillins; C031367:temocillin; D002442:Ceftazidime; D014031:Tobramycin
keywords: Burkholderia cepacia complex; Cystic fibrosis; Eradication; Paediatrics